Adverse Histopathologic Effects of Chemotherapeutic Agents in Childhood Leukemia and Lymphoma

References

• Sutow W. Malignant Solid Tumors in Children; A Review. Raven Press, New York 1981; 9
   Google Scholar
• Levine A. Perspectives on the biology and treatment of cancer in the young: The education of our understanding. Cancer in the Young, A Levine. Masson Publishing USA, New York 1982; xiii–xxxiv
   Google Scholar
• The Medical Letter on Drugs and Therapeutics, M Abramowicz. The Medical Letter, New Rochelle, N.Y. Nov. 28, 1980; Vol. 22, No. 24
   Google Scholar
• Friedman M, Carter S. Serious toxicities associated with chemotherapy. Sem Oncol 1978; 5: 193–202
   PubMedGoogle Scholar
• Brostow M, Mason J, Billingham M, Daniels J. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981; 102: 709–718
   Google Scholar
• Goorin A, Borow K, Goldman A, et al. Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children. Cancer 1981; 47: 2810–2816
   PubMed Web of Science ®Google Scholar
• Fitter W, DeSa D, Pai K. Adriamycin cardiotoxicity: Report of an unusual case with features resembling endomyocardial fibrosis. J Clin Pathol 1981; 34: 602–605
   PubMedGoogle Scholar
• Morgan G, McLlveen B, Freedman A, Murray I. Radionuclide ejection fraction in doxorubicin cardiotoxicity. Cancer Treat Rep 1981; 65: 629–638
   PubMedGoogle Scholar
• Couch R, Loh K, Sugino J. Sudden cardiac death following adriamycin therapy. Cancer 1981; 48: 38–39
   Google Scholar
• Markiewicz W, Robinson E, Peled B, Kaufman S, Carter A. Early detection of doxorubicin cardiotoxicity by M-mode echocardiography. Cancer Chemother Pharmacol 1980; 5: 119–125
   PubMedGoogle Scholar
• Gottlieb S, Fdmiston W, Jr, Harwood L. Late, late doxorubicin cardiotoxicity. Chest 1980; 78: 880–882
   Google Scholar
• Dana B. Adriamycin heart disease: An update. Ariz Med 1980; 37: 416–418
   Google Scholar
• Narahara K, Singer J, Ritchie J, Williams D, Hamiltong G, Kennedy J. Time- and dose-dependent changes in ejection fraction after anthracycline therapy. J Cardiovasc Pharmacol 1979; 1: 395–401
   PubMedGoogle Scholar
• Villani F, Beretta G, Guindani A. Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals. Cancer Chemother Pharmacol 1979; 3: 249–251
   PubMed Web of Science ®Google Scholar
• Friedman J, Ewy G, Jones S, Cruze D, Moon T. 1-year followup of cardiac status after adriamycin therapy. Cancer Treat Rep 1979; 63: 1809–1816
   Google Scholar
• Suzuki T, Kanda H, Kawai Y, Tominasa K, Murata K. Cardiotoxicity of anthracycline antineoplastic drugs—clinicopathological and experimental studies. Jap Circ J 1979; 43: 1000–1008
   PubMedGoogle Scholar
• Wortman J, Lucas V, Jr, Schuster E, Thiele D, Logue G. Sudden death during doxorubicin administration. Cancer 1979; 44: 1588–159
   PubMed Web of Science ®Google Scholar
• Bhanot P, Cushing B, Philippart A, Das L, Farooki Z. Hepatic irradiation and adriamycin cardiotoxicity. J Pediatr 1979; 95: 561–563
   Google Scholar
• Praga C, Beretta G, Viso P, et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979; 63: 827–834
   PubMedGoogle Scholar
• Ulmer H, Ludwig R, Geiger H. Assessment of adriamycin cardiotoxicity in children by systolic time intervals. Eur J Pediatr 1979; 131: 21–31
   Google Scholar
• Kim Y, Lees D, Lake C, Whang-Peng J, Schuette W, Smith R, Bull J. Hyperthermia potentiates doxorubican-related cardiotoxic effects. JAMA 1979; 241: 1816–1817
   PubMed Web of Science ®Google Scholar
• Ali M, Soto A, Maroongroge D, et al. Electrocardiographic changes after adriamycin chemotherapy. Cancer 1979; 43: 465–471
   Google Scholar
• Alexander J, Dainiak N, Berger H, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300: 278–283
   PubMed Web of Science ®Google Scholar
• Lesha S, Benjamin R, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–139
   PubMedGoogle Scholar
• Goorin A, Borow K, Goldman A, et al. Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children. Cancer 1981; 47: 2810–2816
   PubMed Web of Science ®Google Scholar
• Chabner B, Myers C, Coleman C, Johns D. The clinical pharmacology of antineoplastic agents. N Engl J Med 1975; 292: 1107–1113; 1159–1168
   PubMedGoogle Scholar
• Unverferth D, Magoricn R, Unverferth B, et al. Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep 1981; 65: 1093–1097
   PubMedGoogle Scholar
• Mosijczuk A, Ruymann F, Mease A, Bemier R. Anthracycline cardiomyopathy in children: Report of two cases. Cancer 1979; 44: 1582–1587
   PubMedGoogle Scholar
• Von Hoff D, Layard M, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–717
   PubMed Web of Science ®Google Scholar
• Cooper K, Hong W. Prospective study of the pulmonary toxicity of continuously infused hleomycin. Cancer Treat Rep 1981; 65: 419–425
   PubMedGoogle Scholar
• Sostman H, Putman C, Gamsu G. Review: Diagnosis of chemotherapy lung. AJR 1981; 136: 33–40
   PubMed Web of Science ®Google Scholar
• Bennett W, Pastore L, Houghton D. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep 1980; 64: 921–924
   PubMedGoogle Scholar
• Weiss R, Muggia F. Cytotoxic drug-induced pulmonary disease: Update 1980. Am J Med 1980; 68: 259–266
   PubMed Web of Science ®Google Scholar
• Sannohe Y, Hirano M, Shirakusa T, et al. Fatal interstitial pneumonitis induced by low dosage of bleomycin in an esophageal cancer patient. Jap J Surg 1979; 9: 366–371
   PubMedGoogle Scholar
• Ganick D, Peters M, Hafez G. Acute bleomycin toxicity. Am J Pediatr Hcmatol Oncol 1980; 2: 249–252
   PubMedGoogle Scholar
• Perry D, Weiss R, Taylor H. Enhanced bleomycin toxicity during acute renal failure. Cancer Treat Rep 1982; 66: 592–593
   PubMedGoogle Scholar
• Mills B, Roberts R. Cyclophosphamide-induced cardiomyopathy: A report of two cases and review of the English literature. Cancer 1979; 43: 2223–2236
   PubMed Web of Science ®Google Scholar
• Gottdiener J, Appelbaum F, Ferrans V, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758–763
   PubMed Web of Science ®Google Scholar
• Rodin A, Harrage M, Travis L. Lung changes and chemotherapeutic agents in childhood. Am J Dis Child 1970; 120: 337–340
   PubMedGoogle Scholar
• Trompetcr R, Evans P, Barratt T. Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods. Lancet 1981; 1: 1177–1179
   Google Scholar
• Hyman I, Gilbert E. Testicular atrophy in a prcpubescent male after cyclophosphamide therapy. Lancet 1972; 2: 426–427
   PubMedGoogle Scholar
• Platzker A, Landman B, Pysher T. Interstitial pneumonitis and pleural effusion in a one-year-old child with an abdominal tumor. J Pediatr 1981; 98: 497–502
   Google Scholar
• Muller K -M, Menne R, Huthcr W, Grobe H. Fatal pneumopathy after cytostatic treatment for leukemia in children. J Cancer Res Clin Oncol 1979; 94: 287–294
   PubMedGoogle Scholar
• Von Bernuth G, Adam D, Hofstettcr R, et al. Cyclophosphamide cardiotoxicity. Eur J Pediatr 1980; 134: 87–90
   PubMedGoogle Scholar
• Spector J, Zimbler H, Ross J. Early-onset cyclophosphamide-induced interstitial pneumonitis. JAMA 1979; 242: 2852–2854
   PubMedGoogle Scholar
• Flamant-Durand J, Ketelbant-Balasse R, Maurus R. Intracerebral calcifications appearing during the course of acute lymphocytic leukemia treated with methotrexate and X-rays. Cancer 1975; 35: 319–325
   PubMedGoogle Scholar
• Abelson H. Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978; 62: 1999–2001
   PubMedGoogle Scholar
• Saiki J, Thompson S, Smith F, Atkinson R. Paraplegia following intrethecal chemotherapy. Cancer 1972; 29: 370–374
   PubMed Web of Science ®Google Scholar
• Zachariae H, Kraghalle K, Sogaard H. Methotrexate induced liver cirrhosis. Br J Dermatol 1980; 102: 407–412
   PubMed Web of Science ®Google Scholar
• Parker D, Bate C, Craft A, et al. Liver damage in children with acute leukaemia and non-Hodgkin's lymphoma on oral maintenance chemotherapy. Cancer Chemother Pharmacol 1980; 4: 121–127
   PubMed Web of Science ®Google Scholar
• Verdich J, Christensen A. Pulmonary disease complicating intermittent methotrexate therapy of psoriasis. Acta Dermatol Venereol 1979; 59: 471–473
   PubMedGoogle Scholar
• Fox R. Methotrexate nephrotoxicity. Clin Exp Pharmacol Physiol 1979; 5: 43–45
   Google Scholar
• Wall M, Wohl M, Jaffe N, Strieder D. Lung function in adolescents receiving high-dose methotrexate. Pediatrics 1979; 63: 741–746
   PubMedGoogle Scholar
• Bedrossian C, Miller W, Luna M. Methotrexate-induced diffuse interstitial pulmonary fibrosis. South Med J 1979; 72: 313–318
   PubMedGoogle Scholar
• Duttera M, Bleyer W, Pomeroy T. Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet 1973; 2: 703–707
   PubMed Web of Science ®Google Scholar
• Lascari A, Strano A, Johnson W, Collins G. Methotrexate-induced sudden fatal pulmonary reaction. Cancer 1977; 40: 1393–1397
   PubMedGoogle Scholar
• Silver H, Morton D. CCNU nephrotoxicity following sustained remission in oat cell carcinoma. Cancer Treat Rep 1979; 63: 226–227
   PubMedGoogle Scholar
• Legha S, Benjamin R, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–139
   PubMed Web of Science ®Google Scholar